Key result
Intravenous CGRP delayed the onset of myocardial ischaemia during exercise testing, increasing the time to 0.1 mV ST depression from 475 to 546 seconds compared to placebo (p < 0.05).
Why the study?
Does intravenous CGRP improve ischaemia threshold and coronary stenosis severity in patients with chronic stable angina?
Population
12 patients with chronic stable angina, mean age 60 years.
Comparison
Intravenous calcitonin gene related peptide at… vs Intravenous placebo
Design
Other
Authors
Loading...
May raise ischaemia threshold in stable angina; hypothesis-generating for CGRP vasodilation, requiring randomized confirmation before practice change.
RCT (n=12)
Does intravenous CGRP improve ischaemia threshold and coronary stenosis severity in patients with chronic stable angina?
Absolute Event Rate: 546% vs 475%
p-value: p=< 0.05
Intravenous CGRP acts as a systemic arterial vasodilator that dilates coronary arteries at atheromatous stenoses and delays the onset of myocardial ischaemia in patients with chronic stable angina.
Uren et al. (1993) conducted an RCT in chronic stable angina (n=12). Intravenous calcitonin gene related peptide (CGRP) vs. Placebo was evaluated on Time to 0.1 mV ST depression (seconds) (p=< 0.05). Intravenous CGRP delayed the onset of myocardial ischaemia during exercise testing, increasing the time to 0.1 mV ST depression from 475 to 546 seconds compared to placebo (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: